Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Cut by United Capital Financial Advisers LLC

United Capital Financial Advisers LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 98,982 shares of the medical research company’s stock after selling 1,339 shares during the period. United Capital Financial Advisers LLC’s holdings in Thermo Fisher Scientific were worth $29,069,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in TMO. FMR LLC raised its stake in shares of Thermo Fisher Scientific by 33.5% during the 1st quarter. FMR LLC now owns 11,572,581 shares of the medical research company’s stock worth $3,167,647,000 after purchasing an additional 2,900,868 shares in the last quarter. BlackRock Inc. raised its stake in shares of Thermo Fisher Scientific by 4.1% during the 1st quarter. BlackRock Inc. now owns 27,251,678 shares of the medical research company’s stock worth $7,459,327,000 after purchasing an additional 1,074,400 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Thermo Fisher Scientific by 2,589.9% during the 2nd quarter. Jennison Associates LLC now owns 819,138 shares of the medical research company’s stock worth $240,564,000 after purchasing an additional 788,686 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Thermo Fisher Scientific by 361.8% during the 1st quarter. Marshall Wace LLP now owns 775,103 shares of the medical research company’s stock worth $212,161,000 after purchasing an additional 607,245 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Thermo Fisher Scientific by 22.9% during the 2nd quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock worth $877,186,000 after purchasing an additional 555,802 shares in the last quarter. 88.19% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently weighed in on TMO. Wolfe Research began coverage on Thermo Fisher Scientific in a research note on Thursday, May 30th. They issued an “outperform” rating on the stock. Credit Suisse Group reissued a “buy” rating and issued a $310.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Barclays set a $330.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Monday, July 15th. BTIG Research raised their price objective on Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a research note on Thursday, May 23rd. Finally, Needham & Company LLC raised their price objective on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $303.17.

Shares of TMO stock traded up $1.08 during trading on Friday, reaching $296.05. The company had a trading volume of 465,409 shares, compared to its average volume of 1,402,373. The firm’s 50 day simple moving average is $280.90 and its two-hundred day simple moving average is $276.38. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.49 and a quick ratio of 1.07. Thermo Fisher Scientific Inc. has a one year low of $208.34 and a one year high of $305.45. The company has a market capitalization of $115.94 billion, a PE ratio of 26.62, a PEG ratio of 1.89 and a beta of 1.12.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.01 by $0.03. The business had revenue of $6.32 billion for the quarter, compared to the consensus estimate of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The firm’s revenue was up 3.9% compared to the same quarter last year. During the same period last year, the business earned $2.75 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 12.24 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be issued a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.83%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total value of $14,241,500.00. Following the sale, the chief executive officer now owns 342,193 shares of the company’s stock, valued at approximately $97,466,832.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jim P. Manzi sold 1,833 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $272.93, for a total value of $500,280.69. Following the completion of the sale, the director now directly owns 28,592 shares in the company, valued at approximately $7,803,614.56. The disclosure for this sale can be found here. Company insiders own 0.45% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: How does quantitative easing work?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.